Strategic Partnerships Target Syngene’s strong ties with global pharma and biotech players by offering co-development and manufacturing services that complement existing dedicated facilities for big names, highlighting opportunities with Amgen, Bristol-Myers Squibb, GSK, Zoetis, and Merck KGaA.

Scale & Capacity Leverage Syngene’s extensive 2 million sq ft of discovery, development and manufacturing space and large pool of 6000+ scientists to address long-cycle, high-volume CRO/CMO projects for global pharma, biotech and consumer health clients seeking rapid scale.

Leadership Change Position as a partner during leadership transitions by offering continuity in programs and risk-managed outsourcing options, given recent MD/CEO and CHRO/CCO appointments to sustain client confidence and project momentum.

Financial Signals Present value proposition around improved time-to-market and cost of innovation savings, supported by recent quarterlies showing profitability rebounds; align pricing and engagement models with robust data security and quality manufacturing credentials.

Co-Development Opportunities Explore partnerships for MTX240 and other GMP manufacturing capabilities revealed through Biodexa collaboration, emphasizing full-scale CDMO services from API to dosage form, and expanding into gastrointestinal cancer-focused programs where Syngene’s capacity can de-risk timelines.